Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology

This article was originally published in PharmAsia News

Executive Summary

Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Scrip
Pink Sheet
Tags:
Latest Headlines

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

See All
UsernamePublicRestriction

Register

SC073957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By